Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.0970
-0.0014 (-1.42%)
Aug 13, 2026, 5:20 PM CET
Prostatype Genomics AB Market Cap
Prostatype Genomics AB has a market cap or net worth of 5.82 million as of August 13, 2026. Its market cap has decreased by -77.83% in one year.
Market Cap
5.82M
Enterprise Value
2.06M
Revenue
594.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.10
ChartMarket Cap Chart
Since November 3, 2020, Prostatype Genomics AB's market cap has decreased from 92.30M to 5.82M, a decrease of -93.69%. That is a compound annual growth rate of -38.01%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2026 | 5.74M | -67.67% |
| Dec 30, 2025 | 17.76M | -76.14% |
| Dec 30, 2024 | 74.42M | 555.78% |
| Dec 29, 2023 | 11.35M | -76.58% |
| Dec 30, 2022 | 48.46M | -64.07% |
| Dec 30, 2021 | 134.89M | -28.46% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 3, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Swedish Orphan Biovitrum AB | 153.29B |
| Getinge AB | 65.10B |
| Sectra AB | 52.25B |
| Camurus AB | 37.01B |
| Aptahem AB | 16.34M |
| NanoEcho AB | 15.28M |
| Magle Chemoswed Holding AB | 15.13M |
| Luxbright AB | 11.64M |